A Look Into Healthcare Sector Value Stocks
A Look Into Healthcare Sector Value Stocks
Understanding Value Stocks
了解价值股
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
传统上，价值股是根据市场上投资者如何估值该公司的未来增长前景来定义的。低市盈率倍数是表明公司被低估的良好基础指标，很可能被贴上价值股的标签。
The following stocks are considered to be notable value stocks in the healthcare sector:
以下股票被认为是医疗保健领域值得注意的价值股票：
- Kiora Pharmaceuticals (NASDAQ:KPRX) - P/E: 0.84
- Procaps Gr (NASDAQ:PROC) - P/E: 6.16
- InMode (NASDAQ:INMD) - P/E: 9.55
- Alkermes (NASDAQ:ALKS) - P/E: 9.56
- Syros Pharmaceuticals (NASDAQ:SYRS) - P/E: 7.97
- 基奥拉制药（纳斯达克股票代码：KPRX）——市盈率：0.84
- Procaps Gr（纳斯达克股票代码：PROC）——市盈率：6.16
- InMode（纳斯达克股票代码：INMD）——市盈率：9.55
- Alkermes（纳斯达克股票代码：ALKS）——市盈率：9.56
- 锡罗斯制药公司（纳斯达克股票代码：SYRS）——市盈率：7.97
Kiora Pharmaceuticals saw a decrease in earnings per share from -0.79 in Q2 to $-0.89 now. Procaps Gr saw a decrease in earnings per share from 0.27 in Q2 to $0.08 now. Most recently, InMode reported earnings per share at $0.71, whereas in Q3 earnings per share sat at $0.61. Alkermes's earnings per share for Q4 sits at $0.48, whereas in Q3, they were at 0.64. This quarter, Syros Pharmaceuticals experienced a decrease in earnings per share, which was $-1.3 in Q2 and is now $-1.43.
Kiora Pharmicals的每股收益从第二季度的-0.79美元下降至现在的-0.89美元。Procaps Gr的每股收益从第二季度的0.27美元下降至现在的0.08美元。最近，InMode公布的每股收益为0.71美元，而第三季度的每股收益为0.61美元。Alkermes第四季度的每股收益为0.48美元，而第三季度的每股收益为0.64美元。本季度，Syros Pharmicals的每股收益有所下降，第二季度为-1.3美元，目前为-1.43美元。
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.
意义：价值股可能需要一些时间才能从其被低估的位置中反弹。投资价值股的风险在于，这种出现可能永远无法实现。